Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer
Shahanshah Khan, … , Thirumala-Devi Kanneganti, Hasan Zaki
Shahanshah Khan, … , Thirumala-Devi Kanneganti, Hasan Zaki
Published August 15, 2023
Citation Information: J Clin Invest. 2023;133(19):e166295. https://doi.org/10.1172/JCI166295.
View: Text | PDF
Research Article Gastroenterology

NLRP12 downregulates the Wnt/β-catenin pathway via interaction with STK38 to suppress colorectal cancer

  • Text
  • PDF
Abstract

Colorectal cancer (CRC) at advanced stages is rarely curable, underscoring the importance of exploring the mechanism of CRC progression and invasion. NOD-like receptor family member NLRP12 was shown to suppress colorectal tumorigenesis, but the precise mechanism was unknown. Here, we demonstrate that invasive adenocarcinoma development in Nlrp12-deficient mice is associated with elevated expression of genes involved in proliferation, matrix degradation, and epithelial-mesenchymal transition. Signaling pathway analysis revealed higher activation of the Wnt/β-catenin pathway, but not NF-κB and MAPK pathways, in the Nlrp12-deficient tumors. Using Nlrp12–conditional knockout mice, we revealed that NLRP12 downregulates β-catenin activation in intestinal epithelial cells, thereby suppressing colorectal tumorigenesis. Consistent with this, Nlrp12-deficient intestinal organoids and CRC cells showed increased proliferation, accompanied by higher activation of β-catenin in vitro. With proteomic studies, we identified STK38 as an interacting partner of NLRP12 involved in the inhibition of phosphorylation of GSK3β, leading to the degradation of β-catenin. Consistently, the expression of NLRP12 was significantly reduced, while p-GSK3β and β-catenin were upregulated in mouse and human colorectal tumor tissues. In summary, NLRP12 is a potent negative regulator of the Wnt/β-catenin pathway, and the NLRP12/STK38/GSK3β signaling axis could be a promising therapeutic target for CRC.

Authors

Shahanshah Khan, Youn-Tae Kwak, Lan Peng, Shuiqing Hu, Brandi L. Cantarel, Cheryl M. Lewis, Yunpeng Gao, Ram S. Mani, Thirumala-Devi Kanneganti, Hasan Zaki

×

Figure 5

Intestinal epithelial cell–specific NLRP12 suppresses β-catenin activation and colorectal tumorigenesis.

Options: View larger image (or click on image) Download as PowerPoint
Intestinal epithelial cell–specific NLRP12 suppresses β-catenin activati...
(A–G) Vil-Cre (n = 10), Nlrp12fl/fl (n = 12), and Nlrp12fl/fl;Vil-Cre (n = 13) mice were treated with AOM plus DSS to induce colorectal tumorigenesis. (A and B) Tumor burden at 12 weeks after AOM/DSS treatment was counted. (C) Representative H&E-stained images of colorectal tumors. Scale bars: 100 μm. The arrow indicates tumor invasion into the stroma. (D) Percentage of mice showing invasive colorectal adenocarcinoma. (E) Tumor homogenates were analyzed for p-P65, p-ERK, ERK, β-catenin, cyclin D1, cMyc, and β-actin by Western blotting. (F) Densitometric analysis of band intensity of β-catenin, cyclin D1, cMyc, p-P65, and p-ERK. (G) The expression of indicated genes was measured by real-time RT-PCR. Data represent mean ± SEM. Experiments were repeated at least 2 times, and data from a representative experiment are presented. (H–K) HEK293T cells overexpressing GFP or NLRP12 were stimulated with Wnt3a. (H) Cell lysates were analyzed for NLRP12, β-catenin, cMyc, cyclin D1, and β-actin. (I) The localization of β-catenin was analyzed by Western blotting of β-catenin in cytoplasmic and nuclear fractions. (J) Nuclear localization of β-catenin (red) was visualized microscopically. Scale bars: 100 μm. (K) The expression of indicated Wnt target genes was measured by real-time RT-PCR. Data represent mean ± SD of triplicate wells. (L and M) Mouse embryonic fibroblasts (MEFs) from WT and Nlrp12–/– mice were cultured and stimulated with Wnt3a. (L) The activation of β-catenin was measured by Western blotting. (M) The expression of Wnt target genes, including Ctnnb1, Ccnd1, cMyc, Axin2, and MKi67, was measured by real-time RT-PCR. Data represent mean ± SD of triplicate wells. Experiments were repeated 2 times, and data from a representative experiment are presented. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA (B, D, F, and G) or unpaired, 2-tailed Student’s t test (K and M).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts